IART Integra LifeSciences Holdings Corporation

Integra LifeSciences Continues to Make Progress on Its ESG Strategy

Integra LifeSciences Continues to Make Progress on Its ESG Strategy

The company published its third ESG report, underscoring its values and commitment to restoring lives

PRINCETON, N.J., Aug. 21, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: IART), a leading global medical technology company, today issued its latest . The report highlights the company’s 2023 ESG performance and ongoing efforts against the ESG strategy and roadmap established three years ago.

“Innovating treatment pathways to advance patient outcomes and set new standards of care is work that matters to our Integra colleagues around the world and is what drives us each and every day,” said Jan De Witte, president and chief executive officer, Integra LifeSciences. “We are pleased with the advances we have made to meet our ESG commitments and ambitions as we play our part to create healthier people, a healthier workplace and a healthier world.”

Integra’s ESG report includes the past year’s highlights in key areas:

  • Environmental – Recalculated Scope 1, 2 and 3 emissions and partnered with an external consultant to conduct energy assessments at highest energy usage locations to identify energy reduction opportunities and improve greenhouse gas footprint
  • Social – Bolstered diversity and inclusion efforts by adding a new employee resource group and furthering our focus on early-in-career talent by providing support and hands-on experience to diverse college students and graduates
  • Governance – Revised Code of Conduct and continued to strengthen anti-bribery and corruption program through ongoing training curriculums and programs

Integra prepared its ESG report in alignment with external guidelines and measurement frameworks, including the Global Reporting Index and the Sustainability Accounting Standards Board Index.

Read the full report

About Integra

At Integra LifeSciences, we are driven by our purpose of restoring patients’ lives. We innovate treatment pathways to advance patient outcomes and set new standards of surgical, neurologic, and regenerative care. We offer a comprehensive portfolio of high quality, leadership brands. For the latest news and information about Integra and its products, please visit .

Contacts:

Investors:

Chris Ward

(609) 936-2322

Media:

Laurene Isip

(609) 208-8121



EN
21/08/2024

Underlying

Reports on Integra LifeSciences Holdings Corporation

 PRESS RELEASE

Integra LifeSciences Reports Second Quarter 2025 Financial Results

Integra LifeSciences Reports Second Quarter 2025 Financial Results PRINCETON, N.J., July 31, 2025 (GLOBE NEWSWIRE) --  (Nasdaq: IART), a leading global medical technology company, today reported financial results for the second quarter ending June 30, 2025. Second Quarter 2025 Highlights Second quarter revenues exceeded guidance; adjusted earnings per diluted share (EPS) at the top end of the rangeSecond quarter revenues of $415.6 million decreased (0.6)% on a reported basis and (1.4)% on an organic basis compared to the prior year.Second quarter GAAP earnings per diluted share of $...

 PRESS RELEASE

Integra LifeSciences to Host Second Quarter 2025 Financial Results Con...

Integra LifeSciences to Host Second Quarter 2025 Financial Results Conference Call on July 31, 2025 PRINCETON, N.J., July 14, 2025 (GLOBE NEWSWIRE) --  (NASDAQ: IART), a leading global medical technology company, will release second quarter 2025 financial results on Thursday, July 31, 2025, prior to the market open. In conjunction with the earnings release, Integra’s management team will host a conference call at 8:30 a.m. ET. A live webcast will be available on the Investors section of the Company’s website at . For those planning to participate on the call, register  to receive dial-in...

 PRESS RELEASE

Integra LifeSciences Announces First Patient Enrolled in Acclarent AER...

Integra LifeSciences Announces First Patient Enrolled in Acclarent AERA® Pediatric Registry PRINCETON, N.J., July 02, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: IART), a leading global medical technology company, is proud to announce enrollment of the first patient in the Acclarent AERA Pediatric Registry, a prospective, multi-center observational registry evaluating the real-world use of the in children. This inaugural enrollment marks the focused effort to measure the ongoing, real-world clinical performance of AERA in pediatric patients with obstructive Eustachian tube dysfunction (ETD). Dr....

 PRESS RELEASE

Integra LifeSciences Reports First Quarter 2025 Financial Results

Integra LifeSciences Reports First Quarter 2025 Financial Results PRINCETON, N.J., May 05, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: IART), a leading global medical technology company, today reported financial results for the first quarter ending March 31, 2025. First Quarter 2025 Highlights First quarter revenues of $382.7 million increased 3.7% on a reported basis and decreased 3.5% on an organic basis compared to the prior year. First quarter GAAP earnings per diluted share of $(0.33), compared to $(0.04) in the prior year; adjusted earnings per diluted share of $0.41, compared to $0.55...

 PRESS RELEASE

Integra LifeSciences to Host First Quarter 2025 Financial Results Conf...

Integra LifeSciences to Host First Quarter 2025 Financial Results Conference Call on May 5, 2025 PRINCETON, N.J., April 18, 2025 (GLOBE NEWSWIRE) --  (NASDAQ: IART), a leading global medical technology company, will release first quarter 2025 financial results on Monday, May 5, 2025, prior to the market open. In conjunction with the earnings release, Integra’s management team will host a conference call at 8:30 a.m. ET. A live webcast will be available on the Investors section of the Company’s website at . For those planning to participate on the call, register  to receive dial-in detail...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch